Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)
The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustl...
Saved in:
| Published in | Cardiovascular diabetology Vol. 22; no. 1; pp. 194 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central
31.07.2023
BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD.
The Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m
≤ estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m
and 30 mg/g Cr ≤ urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR < 60 mL/min/1.73 m
or at 20 mg once daily in those with a baseline eGFR ≥ 60 mL/min/1.73 m
) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink® Target 96 panels will be also performed.
FIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials. Trial registration Unique Trial Number, NCT05887817 ( https://clinicaltrials.gov/ct2/show/NCT05887817 ) and jRCTs021230011 ( https://jrct.niph.go.jp/latest-detail/jRCTs021230011 ). |
|---|---|
| AbstractList | BackgroundThe overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD.MethodsThe Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m2 ≤ estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m2 and 30 mg/g Cr ≤ urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR < 60 mL/min/1.73 m2 or at 20 mg once daily in those with a baseline eGFR ≥ 60 mL/min/1.73 m2) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink® Target 96 panels will be also performed.DiscussionFIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials.Trial registration Unique Trial Number, NCT05887817 (https://clinicaltrials.gov/ct2/show/NCT05887817) and jRCTs021230011 (https://jrct.niph.go.jp/latest-detail/jRCTs021230011). The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD.BACKGROUNDThe overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD.The Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m2 ≤ estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m2 and 30 mg/g Cr ≤ urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR < 60 mL/min/1.73 m2 or at 20 mg once daily in those with a baseline eGFR ≥ 60 mL/min/1.73 m2) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink® Target 96 panels will be also performed.METHODSThe Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m2 ≤ estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m2 and 30 mg/g Cr ≤ urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR < 60 mL/min/1.73 m2 or at 20 mg once daily in those with a baseline eGFR ≥ 60 mL/min/1.73 m2) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink® Target 96 panels will be also performed.FIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials. Trial registration Unique Trial Number, NCT05887817 ( https://clinicaltrials.gov/ct2/show/NCT05887817 ) and jRCTs021230011 ( https://jrct.niph.go.jp/latest-detail/jRCTs021230011 ).DISCUSSIONFIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials. Trial registration Unique Trial Number, NCT05887817 ( https://clinicaltrials.gov/ct2/show/NCT05887817 ) and jRCTs021230011 ( https://jrct.niph.go.jp/latest-detail/jRCTs021230011 ). The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD. The Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m ≤ estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m and 30 mg/g Cr ≤ urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR < 60 mL/min/1.73 m or at 20 mg once daily in those with a baseline eGFR ≥ 60 mL/min/1.73 m ) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink® Target 96 panels will be also performed. FIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials. Trial registration Unique Trial Number, NCT05887817 ( https://clinicaltrials.gov/ct2/show/NCT05887817 ) and jRCTs021230011 ( https://jrct.niph.go.jp/latest-detail/jRCTs021230011 ). Abstract Background The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD. Methods The Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m2 ≤ estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m2 and 30 mg/g Cr ≤ urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR < 60 mL/min/1.73 m2 or at 20 mg once daily in those with a baseline eGFR ≥ 60 mL/min/1.73 m2) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink® Target 96 panels will be also performed. Discussion FIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials. Trial registration Unique Trial Number, NCT05887817 ( https://clinicaltrials.gov/ct2/show/NCT05887817 ) and jRCTs021230011 ( https://jrct.niph.go.jp/latest-detail/jRCTs021230011 ). |
| ArticleNumber | 194 |
| Author | Kida, Keisuke Tanaka, Kenichi Moroi, Masao Shibata, Hirotaka Tanabe, Kengo Node, Koichi Okada, Yosuke Taguchi, Isao Teragawa, Hiroki Shimabukuro, Michio Suwa, Satoru Toyoda, Shigeru Nangaku, Masaomi Yoshida, Hisako Takahashi, Naohiko Imai, Takumi Miyazono, Motoaki Tanaka, Atsushi Fukuda, Daiju |
| Author_xml | – sequence: 1 givenname: Atsushi surname: Tanaka fullname: Tanaka, Atsushi – sequence: 2 givenname: Hirotaka surname: Shibata fullname: Shibata, Hirotaka – sequence: 3 givenname: Takumi surname: Imai fullname: Imai, Takumi – sequence: 4 givenname: Hisako surname: Yoshida fullname: Yoshida, Hisako – sequence: 5 givenname: Motoaki surname: Miyazono fullname: Miyazono, Motoaki – sequence: 6 givenname: Naohiko surname: Takahashi fullname: Takahashi, Naohiko – sequence: 7 givenname: Daiju surname: Fukuda fullname: Fukuda, Daiju – sequence: 8 givenname: Yosuke surname: Okada fullname: Okada, Yosuke – sequence: 9 givenname: Hiroki surname: Teragawa fullname: Teragawa, Hiroki – sequence: 10 givenname: Satoru surname: Suwa fullname: Suwa, Satoru – sequence: 11 givenname: Keisuke surname: Kida fullname: Kida, Keisuke – sequence: 12 givenname: Masao surname: Moroi fullname: Moroi, Masao – sequence: 13 givenname: Isao surname: Taguchi fullname: Taguchi, Isao – sequence: 14 givenname: Shigeru surname: Toyoda fullname: Toyoda, Shigeru – sequence: 15 givenname: Michio surname: Shimabukuro fullname: Shimabukuro, Michio – sequence: 16 givenname: Kengo surname: Tanabe fullname: Tanabe, Kengo – sequence: 17 givenname: Kenichi surname: Tanaka fullname: Tanaka, Kenichi – sequence: 18 givenname: Masaomi surname: Nangaku fullname: Nangaku, Masaomi – sequence: 19 givenname: Koichi surname: Node fullname: Node, Koichi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37525257$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1r3DAQxd2S0ny00HMPRdBLCnFryZYtn0oISRsIFNK0VyFL440SrbSR5IXtX9_Z3TQkORRj7LHe_Pw0evvFjg8eiuI9rT5TKtovibK-rsuK4U17JsrVy2KPNh0vmWiqnUfvu8V-SjdVRTvR0tfFbt1xhle39-Ldpco2eOWAKG-IgWRnnoQRK2L9ElK2M5VDLK232aoM5ojMJ5etBp8hHpFFDGkBOtslYOGUhiGUOvgcg3NrtQnT4KAcnPVYRfxLmNs_YEiOVjmSA4GlchOiSb4GAuOItLS2MFoPEdabJsGTpUp6cioStDSOHlLaONYqGhtQhqzBhrmKtxATeid5tQDCiLFqgAz36usYvNXk1hoPK1xLoBKQw7Pz36flz6vjy09vilejcgne3j8Pil9np1cn38uLH9_OT44vSt3WVS4Ng7plDeO8M1wz3VMGrOGsFuOg2qoZOHBW9cwY0Q9Vp3kP7cDNyDsAEF1XHxTnW64J6kYuokXnKxmUlZsPIc6kijhmB7KitO07ppu6p43Rg2gawQVtWt6PdBgEsr5uWYtpmINZH01U7gn06Yq313IWlpJWiBSiQsLhPSGGuwlPXc5t0uCc8hCmJDFETdv1nK6Nf3wmvQlTxPGvVbjnTtQ4hoPiw2NLD17-JQ8FbCvQGKAUYXyQ0Equ4y238ZYYb7mJt1xhk3jWpG3eBBi3Zd3_Wv8CNs8D8Q |
| CitedBy_id | crossref_primary_10_3390_jcm13216398 crossref_primary_10_55905_cuadv16n12_021 crossref_primary_10_1007_s12325_024_03084_5 crossref_primary_10_1007_s11255_025_04456_8 crossref_primary_10_1111_jdi_14231 |
| Cites_doi | 10.1056/NEJMoa2024816 10.1002/cmdc.201200081 10.1093/eurheartj/ehac495 10.1093/ehjcvp/pvac059 10.1093/eurheartj/ehab777 10.1016/j.jchf.2020.11.010 10.1016/j.jchf.2021.04.014 10.1056/NEJMoa2025845 10.1111/bcp.14194 10.1016/j.jchf.2021.02.016 10.1016/j.jacc.2023.03.393 10.7326/M22-2904 10.5551/jat.44834 10.5551/jat.5983 10.1097/HJH.0000000000001437 10.1038/ajh.2011.245 10.1097/HJH.0000000000000651 10.5551/jat.29926 10.1056/NEJMoa2110956 10.1016/j.jdiacomp.2019.05.009 10.1111/dom.14601 10.1056/NEJMoa1811744 10.1016/j.kint.2019.02.030 10.1093/ndt/gfab336 10.1056/NEJMoa2204233 10.1016/j.kint.2022.08.012 10.1111/jdi.13355 10.1097/HJH.0000000000001989 10.1186/s12882-016-0337-0 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| CorporateAuthor | the FIVE-STAR trial investigators FIVE-STAR trial investigators |
| CorporateAuthor_xml | – name: the FIVE-STAR trial investigators – name: FIVE-STAR trial investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12933-023-01928-y |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1475-2840 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_0116972c43914dcb84485814659f1bb8 PMC10391880 37525257 10_1186_s12933_023_01928_y |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 0R~ 29B 2WC 53G 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c630t-d2e36242557d5c2c912e245238fba604b5e52092dd89b07c59e6b5df57eee8773 |
| IEDL.DBID | M48 |
| ISSN | 1475-2840 |
| IngestDate | Wed Aug 27 01:29:34 EDT 2025 Thu Aug 21 18:42:14 EDT 2025 Thu Jul 10 19:28:05 EDT 2025 Fri Jul 25 10:33:53 EDT 2025 Mon Jul 21 05:56:59 EDT 2025 Thu Apr 24 22:53:30 EDT 2025 Tue Jul 01 04:19:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Type 2 diabetes Biomarker Chronic kidney disease Finerenone Vascular stiffness |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c630t-d2e36242557d5c2c912e245238fba604b5e52092dd89b07c59e6b5df57eee8773 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2852078352?pq-origsite=%requestingapplication% |
| PMID | 37525257 |
| PQID | 2852078352 |
| PQPubID | 42570 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0116972c43914dcb84485814659f1bb8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10391880 proquest_miscellaneous_2844679517 proquest_journals_2852078352 pubmed_primary_37525257 crossref_primary_10_1186_s12933_023_01928_y crossref_citationtrail_10_1186_s12933_023_01928_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-07-31 |
| PublicationDateYYYYMMDD | 2023-07-31 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Cardiovascular diabetology |
| PublicationTitleAlternate | Cardiovasc Diabetol |
| PublicationYear | 2023 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | K Takahashi (1928_CR18) 2019; 26 CE Mills (1928_CR25) 2020; 86 H Li (1928_CR1) 2021; 12 A Chaudhuri (1928_CR2) 2022; 24 KJ Kim (1928_CR16) 2011; 18 V Perkovic (1928_CR4) 2019; 380 SD Navaneethan (1928_CR7) 2023; 176 MM Kittleson (1928_CR29) 2023; 81 PA Heidenreich (1928_CR11) 2022; 145 JA Requena-Ibáñez (1928_CR23) 2021; 9 F Zannad (1928_CR28) 2022; 43 H Shibata (1928_CR9) 2012; 25 J Barrera-Chimal (1928_CR8) 2019; 96 P Wohlfahrt (1928_CR21) 2017; 35 R Agarwal (1928_CR30) 2022; 37 WG Herrington (1928_CR6) 2023; 388 G Currie (1928_CR10) 2016; 17 IH de Boer (1928_CR3) 2022; 102 GL Bakris (1928_CR13) 2020; 383 HJL Heerspink (1928_CR5) 2020; 383 K Hayashi (1928_CR17) 2015; 33 L Bärfacker (1928_CR12) 2012; 7 S Kishimoto (1928_CR26) 2019; 37 SL Chung (1928_CR20) 2015; 22 R Agarwal (1928_CR15) 2022; 43 B Pitt (1928_CR14) 2021; 385 NH Brandt-Jacobsen (1928_CR19) 2021; 9 JP Ferreira (1928_CR27) 2021; 9 A Tanaka (1928_CR22) 2023; 9 C Zhang (1928_CR24) 2019; 33 |
| References_xml | – volume: 383 start-page: 1436 issue: 15 year: 2020 ident: 1928_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa2024816 – volume: 7 start-page: 1385 issue: 8 year: 2012 ident: 1928_CR12 publication-title: ChemMedChem doi: 10.1002/cmdc.201200081 – volume: 43 start-page: 4991 issue: 48 year: 2022 ident: 1928_CR28 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehac495 – volume: 9 start-page: 165 issue: 2 year: 2023 ident: 1928_CR22 publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvac059 – volume: 43 start-page: 474 issue: 6 year: 2022 ident: 1928_CR15 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab777 – volume: 9 start-page: 268 issue: 4 year: 2021 ident: 1928_CR27 publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2020.11.010 – volume: 9 start-page: 578 issue: 8 year: 2021 ident: 1928_CR23 publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2021.04.014 – volume: 383 start-page: 2219 issue: 23 year: 2020 ident: 1928_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa2025845 – volume: 86 start-page: 891 issue: 5 year: 2020 ident: 1928_CR25 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14194 – volume: 9 start-page: 550 issue: 8 year: 2021 ident: 1928_CR19 publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2021.02.016 – volume: 81 start-page: 1835 issue: 18 year: 2023 ident: 1928_CR29 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2023.03.393 – volume: 176 start-page: 381 issue: 3 year: 2023 ident: 1928_CR7 publication-title: Ann Intern Med doi: 10.7326/M22-2904 – volume: 26 start-page: 465 issue: 5 year: 2019 ident: 1928_CR18 publication-title: J Atheroscler Thromb doi: 10.5551/jat.44834 – volume: 18 start-page: 328 issue: 4 year: 2011 ident: 1928_CR16 publication-title: J Atheroscler Thromb doi: 10.5551/jat.5983 – volume: 35 start-page: 2238 issue: 11 year: 2017 ident: 1928_CR21 publication-title: J Hypertens doi: 10.1097/HJH.0000000000001437 – volume: 25 start-page: 514 issue: 5 year: 2012 ident: 1928_CR9 publication-title: Am J Hypertens doi: 10.1038/ajh.2011.245 – volume: 33 start-page: 1742 issue: 9 year: 2015 ident: 1928_CR17 publication-title: J Hypertens doi: 10.1097/HJH.0000000000000651 – volume: 145 start-page: e895 issue: 18 year: 2022 ident: 1928_CR11 publication-title: Circulation – volume: 22 start-page: 1255 issue: 12 year: 2015 ident: 1928_CR20 publication-title: J Atheroscler Thromb doi: 10.5551/jat.29926 – volume: 385 start-page: 2252 issue: 24 year: 2021 ident: 1928_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa2110956 – volume: 33 start-page: 623 issue: 9 year: 2019 ident: 1928_CR24 publication-title: J Diabetes Complications doi: 10.1016/j.jdiacomp.2019.05.009 – volume: 24 start-page: 365 issue: 3 year: 2022 ident: 1928_CR2 publication-title: Diabetes Obes Metab doi: 10.1111/dom.14601 – volume: 380 start-page: 2295 issue: 24 year: 2019 ident: 1928_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1811744 – volume: 96 start-page: 302 issue: 2 year: 2019 ident: 1928_CR8 publication-title: Kidney Int doi: 10.1016/j.kint.2019.02.030 – volume: 37 start-page: 1261 issue: 7 year: 2022 ident: 1928_CR30 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfab336 – volume: 388 start-page: 117 issue: 2 year: 2023 ident: 1928_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa2204233 – volume: 102 start-page: 974 issue: 5 year: 2022 ident: 1928_CR3 publication-title: Kidney Int doi: 10.1016/j.kint.2022.08.012 – volume: 12 start-page: 346 issue: 3 year: 2021 ident: 1928_CR1 publication-title: J Diabetes Investig doi: 10.1111/jdi.13355 – volume: 37 start-page: 1083 issue: 5 year: 2019 ident: 1928_CR26 publication-title: J Hypertens doi: 10.1097/HJH.0000000000001989 – volume: 17 start-page: 127 issue: 1 year: 2016 ident: 1928_CR10 publication-title: BMC Nephrol doi: 10.1186/s12882-016-0337-0 |
| SSID | ssj0017861 |
| Score | 2.370649 |
| Snippet | The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting... BackgroundThe overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by... Abstract Background The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 194 |
| SubjectTerms | Ankle Biomarker Biomarkers Blood pressure Chronic kidney disease Clinical trials Consent Creatinine Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - diagnosis Diabetic Nephropathies - drug therapy Double-Blind Method Double-blind studies Drug dosages Drug therapy Ejection fraction Epidermal growth factor receptors Finerenone Humans Inflammation Kidney diseases Mineralocorticoid receptors Mortality Patients Placebos Potassium Prospective Studies Proteomics Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - drug therapy Study Protocol Type 2 diabetes Vascular Stiffness |
| SummonAdditionalLinks | – databaseName: DOAJ - Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEDaoB8SF9yOloEHiAKIRiRMnzrGgrgpSOZQW9Wat44mIWBK0j8P21zPjOFEXIbhw9GZ2d5xM7Hl881mIV5KWvCYtyHPDSsf5PJnTOshchCkWupauyhvuHT79XJxc5J8u1eW1o74YEzbQAw83jg8qLapS1twhmrvaaoonFOetVNWk1vo2X9rzxmAq1A9KXaRji4wu3q14V-N6JWOHKqnj7c425Nn6_-Ri_o6UvLb1zO6JO8FnhKNB1_viJnYPxK3TUBV_eOPuWcjoIcw7B86DMqBvaATtxKPRL-OWkULkXLpD8EBC_j9cHgJpNHZc0oAT67aPA4h9wdKu39gFxpZ8UhrR9ub6H-0VOvCHfsC6h8AajkAOJQSQCKvQcHMhdn2H0Hcw4l6BVGoaXmW9xrUHxZIY_RbzATBkaLki3YEzxCBhzBAP0gOfL3xvXYdbCCUmeD37-PU4_nJ-dPbmkbiYHZ9_OInDSQ9xXWTJOnYSM25UUap0qpZ1lUrkknCmGzsvktwqZLiOdE5XNilrVWFhlWtUiYi6LLPHYo9n8lSAS5TLK_I8KOzPsUKNGUVMEnXupNaujEQ6PnhTBxp0Po1jYXw4pAszGIshYzHeWMw2Em-n7_wcSED-Kv2e7WmSZAJv_wGZtQlmbf5l1pE4GK3RhFVlZaSmu8CpOhmJl9NlWg-4yDPvsN-wDAX4JfnNNNMng_FOmmSlksx-Gwm9Y9Y7qu5e6dpvnnOcEQNM3bf_Pyb3TNyW_l3kFPmB2FsvN_icfLu1feFf41-PN01K priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEDZQJMSF92OhoEHiAKJRN04cOydUUFcFqRxKi3qL1vEEVixx2cdh-fXMOE5gEeoxm9ndiTIez-Obz0K8lOTymrSgyA1Lk-TT8ZT8IHMRpliYWroyb3h2-PhTcXSWfzxX57Hgtoywyt4nBkftfM018n1plOSWk5JvL34mfGoUd1fjERrXxHWmLmNIlz4fEq5UmyLtB2VMsb_kvY27lowgKqVJNlubUeDs_1-g-S9e8q8NaHJH3IqRIxx0r_quuIrtPXHjOPbG71-5fRLregjT1oEL0AzwDV3BbGDT8ItkxnghCjHdHgQ4If8fLvaANOrnLumCy-vWJxHKPmdp59d2jomlyJSuaJNz_sfsFzoIR3_AykPkDkegsBIiVIRVaHjEEFvfIvgWevQrkEpNw742aFwHaCyJ0W8xKwADhxZL0h24TgwS-jpxJ92x-sL3mWtxA7HRBK8mH74cJp9PD05ePxBnk8PT90dJPO8hqYtsvEqcxIzHVZTSTtWyLlOJ3BjOTGOnxTi3Chm0I50zpR3rWpVYWOUapRHRaJ09FDv8JI8FuLFyeUnxByX_OZZoMKO8SaLJnTTG6ZFI-xdf1ZEMnc_kmFchKTJF1RlLRcZSBWOpNiPxZvjORUcFcqn0O7anQZJpvMMHfvG1il6h4i5YqWXN48-5q62hZFlxUVaVTWqtGYnd3hqr6FuW1Z-VMBIvhtvkFbjVM23Rr1mG0nxN0TM96aPOeAdNMq0kc-COhNky6y1Vt--0s2-BeZxxA0zg9-RyvZ6KmzKsMi6B74qd1WKNzyh2W9nnYYH-Bi0YRoE priority: 102 providerName: ProQuest |
| Title | Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37525257 https://www.proquest.com/docview/2852078352 https://www.proquest.com/docview/2844679517 https://pubmed.ncbi.nlm.nih.gov/PMC10391880 https://doaj.org/article/0116972c43914dcb84485814659f1bb8 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwEDf7kKa98P1RGJWReACxjMSJY-cBoQ21GkidUFlR36I6vrBqJYG0lSh_PXdOUigqPKa5pJfkzj7f_e5nxp4LHPLyIMbIDRLtRRN_guMgcREGEOtM2CTKqXd4cBGfj6IPYzneYe12R80LnG9d2tF-UqNqdvLj--otOvwb5_A6fj2nOYuqkYQMSoT2VrtsH2cmRY46iH5XFZSOg7ZxZut1h-wgVFIQQ-jGPOXo_LfFoH9DKf-Ym_q32c0mqOSntRXcYTtQ3GUHg6Zsfu_GrWGT8gM-KSy3DrXByxyP-HRNtFFW3pSgRBh92mPukIb0f1Adc9SobcnEA8q8m9JrUO4zkrbl0szAMxi04hHOf7b8Ov0JlrtdQfii5A2tOHCMOHmDIiEVcuo-hKIsgJcFb4GxHFXKcxqGncaZQ82iGN6LCAMIU1TNUXdOKWQueJtCrqVrwl9-PbUFrHhTg-Iv-u8_97xPl6fDl_fZqN-7fHfuNVtBeFkc-gvPCgipk0VKZWUmsiQQQDXjUOdmEvuRkUB4HmGtToyvMplAbKTNpQIArVT4gO3Rkzxi3PrSRgmGJnHiR5CAhhCXVAJ0ZIXWVnVY0H74NGt40mm7jlnq1ks6Tmu7SdFuUmc36arDXq2v-VazhPxX-ozsaS1JDN_uh7L6kjYDRkoFskSJjDqjI5sZjetoSflameSBMbrDjlprTFuvSYXGt0C5PNFhz9anccCgKtCkgHJJMhFOjhhY45M-rI13rUlr_B2mN8x6Q9XNM8X0ypGSE6SAuP0e__OmT9ihcL5GifEjtreolvAUI7qF6bJdNVZdtn_Wu_g47Lq8SNe57i_GE01A |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5KKgEX3o9AgUUCCUSt2muvvT4g1EKihDYRCinqzcTeMUQEu-QhFH4Uv5GZ9doQhHrrceOxM5ZnZ-fxzQxjTwWqvNwL0XKDWDnBxJ2gHqRehB6EKhM6DnKqHR4Mw95x8O5EnmyxX3UtDMEqa51oFLUuM4qR7wklBaWcpHh9-t2hqVGUXa1HaFRicQjrH-iyLV713-L3fSZEtzN-03PsVAEnC3136WgBPhVFSBlpmYks9gRQ-tFXeToJ3SCVQNAQobWKUzfKZAxhKnUuIwBQUeTjcy-y7cBHV6bFtg86w_ejJm8RqdCrS3NUuLeg05TypIRZioVy1hvHn5kS8D_T9l-E5l9HXvc6u2ptVb5fCdcNtgXFTXZpYLPxty5cG9lIIvBJobk2YBBe5rji06Z_Rzl3poRQQqNW73IDYKT_g_kuR47qSk9cUEA_LR0Lnp8RtS5X6QycFG1hXOGxqstv05-guRk2wpclt93KgaMhyy04hVjIqagRirIAXha8xttyZCnPSbsbjjMDxkUyfBb1ISCo0nyBvHOKTHPB68h0RV31EeZfp7qANbepLf682__YcT6M90cvbrPjc5GFO6xFb3KPce1KHcRo8YSxG0AMCnz01ASoQAuldNRmXv3hk8y2X6cpILPEuGEqTCphSVBYEiMsybrNXjb3nFbNR86kPiB5aiipcbj5oZx_TqweSijvFkcio4LrQGepQvdcUhhYxrmXpqrNdmppTKw2WyR_9l6bPWkuox6i5NKkgHJFNAGeuWiv45verYS34cSPpKCuu22mNsR6g9XNK8X0i-l1TkgFahl4_2y-HrPLvfHgKDnqDw8fsCvC7DgKwO-w1nK-godoOS7TR3a7cvbpvDXEb-ypg-Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rationale+and+design+of+an+investigator-initiated%2C+multicenter%2C+prospective%2C+placebo-controlled%2C+double-blind%2C+randomized+trial+to+evaluate+the+effects+of+finerenone+on+vascular+stiffness+and+cardiorenal+biomarkers+in+type+2+diabetes+and+chronic+kidney+disease+%28FIVE-STAR%29&rft.jtitle=Cardiovascular+diabetology&rft.au=Tanaka%2C+Atsushi&rft.au=Shibata%2C+Hirotaka&rft.au=Imai%2C+Takumi&rft.au=Yoshida%2C+Hisako&rft.date=2023-07-31&rft.eissn=1475-2840&rft.volume=22&rft.issue=1&rft.spage=194&rft_id=info:doi/10.1186%2Fs12933-023-01928-y&rft_id=info%3Apmid%2F37525257&rft.externalDocID=37525257 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2840&client=summon |